Headlines about Clovis Oncology (NASDAQ:CLVS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Clovis Oncology earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.3340274835421 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

Shares of CLVS traded down $0.12 during mid-day trading on Friday, hitting $35.25. 513,878 shares of the company’s stock were exchanged, compared to its average volume of 1,231,350. The stock has a market capitalization of $1.83 billion, a PE ratio of -6.88 and a beta of 1.25. Clovis Oncology has a fifty-two week low of $33.85 and a fifty-two week high of $86.26. The company has a debt-to-equity ratio of 1.84, a quick ratio of 9.21 and a current ratio of 10.03.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.56). The business had revenue of $23.76 million for the quarter, compared to analyst estimates of $22.44 million. Clovis Oncology had a negative return on equity of 94.28% and a negative net margin of 382.83%. The firm’s revenue for the quarter was up 62.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.29) EPS. sell-side analysts predict that Clovis Oncology will post -6.77 earnings per share for the current year.

A number of research analysts have commented on CLVS shares. Gabelli reaffirmed a “buy” rating on shares of Clovis Oncology in a research report on Monday, July 16th. Credit Suisse Group set a $86.00 target price on shares of Clovis Oncology and gave the company a “buy” rating in a research report on Thursday, April 26th. Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Tuesday, May 1st. Royal Bank of Canada reaffirmed a “buy” rating and issued a $73.00 target price on shares of Clovis Oncology in a research report on Tuesday, June 12th. Finally, Cann reaffirmed a “hold” rating on shares of Clovis Oncology in a research report on Monday, June 11th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $79.65.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Further Reading: Price to Earnings Ratio (PE) Basics

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.